Norethindrone And Ethinyl Estradiol And Ferrous Fumarate is a drug owned by Teva Branded Pharmaceutical Products R And D Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 06, 2019. Details of Norethindrone And Ethinyl Estradiol And Ferrous Fumarate's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6667050 | Chewable oral contraceptive |
Apr, 2019
(5 years ago) |
Expired
|
| US5552394 | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul, 2014
(10 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Norethindrone And Ethinyl Estradiol And Ferrous Fumarate's patents.
Latest Legal Activities on Norethindrone And Ethinyl Estradiol And Ferrous Fumarate's Patents
Given below is the list of recent legal activities going on the following patents of Norethindrone And Ethinyl Estradiol And Ferrous Fumarate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| File Marked Found | 20 Jan, 2016 | US6667050 (Litigated) |
| File Marked Found | 17 Dec, 2015 | US6667050 (Litigated) |
| Change in Power of Attorney (May Include Associate POA) Critical | 30 Apr, 2010 | US6667050 (Litigated) |
| Correspondence Address Change Critical | 29 Apr, 2010 | US6667050 (Litigated) |
| Patent Issue Date Used in PTA Calculation Critical | 23 Dec, 2003 | US6667050 (Litigated) |
| Recordation of Patent Grant Mailed Critical | 23 Dec, 2003 | US6667050 (Litigated) |
| Issue Notification Mailed Critical | 04 Dec, 2003 | US6667050 (Litigated) |
| Receipt into Pubs | 14 Nov, 2003 | US6667050 (Litigated) |
| Application Is Considered Ready for Issue Critical | 13 Nov, 2003 | US6667050 (Litigated) |
| Receipt into Pubs | 07 Oct, 2003 | US6667050 (Litigated) |
FDA has granted several exclusivities to Norethindrone And Ethinyl Estradiol And Ferrous Fumarate. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Norethindrone And Ethinyl Estradiol And Ferrous Fumarate, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Norethindrone And Ethinyl Estradiol And Ferrous Fumarate.
Exclusivity Information
Norethindrone And Ethinyl Estradiol And Ferrous Fumarate holds 1 exclusivities. All of its exclusivities have expired in 2013. Details of Norethindrone And Ethinyl Estradiol And Ferrous Fumarate's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 22, 2013 |
US patents provide insights into the exclusivity only within the United States, but Norethindrone And Ethinyl Estradiol And Ferrous Fumarate is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Norethindrone And Ethinyl Estradiol And Ferrous Fumarate's family patents as well as insights into ongoing legal events on those patents.
Norethindrone And Ethinyl Estradiol And Ferrous Fumarate's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Norethindrone And Ethinyl Estradiol And Ferrous Fumarate's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 06, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Norethindrone And Ethinyl Estradiol And Ferrous Fumarate Generic API suppliers:
Ethinyl Estradiol; Norethindrone is the generic name for the brand Norethindrone And Ethinyl Estradiol And Ferrous Fumarate. 16 different companies have already filed for the generic of Norethindrone And Ethinyl Estradiol And Ferrous Fumarate, with Barr having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Norethindrone And Ethinyl Estradiol And Ferrous Fumarate's generic
Alternative Brands for Norethindrone And Ethinyl Estradiol And Ferrous Fumarate
Norethindrone And Ethinyl Estradiol And Ferrous Fumarate which is used for preventing pregnancy in women using oral contraceptives., has several other brand drugs in the same treatment category and using the same active ingredient (Ethinyl Estradiol; Norethindrone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Teva Branded Pharm |
| |||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Ethinyl Estradiol; Norethindrone. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |||||
|---|---|---|---|---|---|---|
| Apil |
| |||||
| Teva Branded Pharm |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Ethinyl Estradiol; Norethindrone, Norethindrone And Ethinyl Estradiol And Ferrous Fumarate's active ingredient. Check the complete list of approved generic manufacturers for Norethindrone And Ethinyl Estradiol And Ferrous Fumarate
About Norethindrone And Ethinyl Estradiol And Ferrous Fumarate
Norethindrone And Ethinyl Estradiol And Ferrous Fumarate is a drug owned by Teva Branded Pharmaceutical Products R And D Inc. It is used for preventing pregnancy in women using oral contraceptives. Norethindrone And Ethinyl Estradiol And Ferrous Fumarate uses Ethinyl Estradiol; Norethindrone as an active ingredient. Norethindrone And Ethinyl Estradiol And Ferrous Fumarate was launched by Teva Branded Pharm in 2010.
Approval Date:
Norethindrone And Ethinyl Estradiol And Ferrous Fumarate was approved by FDA for market use on 22 December, 2010.
Active Ingredient:
Norethindrone And Ethinyl Estradiol And Ferrous Fumarate uses Ethinyl Estradiol; Norethindrone as the active ingredient. Check out other Drugs and Companies using Ethinyl Estradiol; Norethindrone ingredient
Treatment:
Norethindrone And Ethinyl Estradiol And Ferrous Fumarate is used for preventing pregnancy in women using oral contraceptives.
Dosage:
Norethindrone And Ethinyl Estradiol And Ferrous Fumarate is available in tablet, chewable form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.025MG;0.8MG | TABLET, CHEWABLE | Prescription | ORAL |